

Alejandro Soto-Gutierrez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7103446/publications.pdf>

Version: 2024-02-01

33
papers

1,582
citations

361045

20
h-index

414034

32
g-index

33
all docs

33
docs citations

33
times ranked

2507
citing authors

#	ARTICLE	IF	CITATIONS
1	A Whole-Organ Regenerative Medicine Approach for Liver Replacement. <i>Tissue Engineering - Part C: Methods</i> , 2011, 17, 677-686.	1.1	280
2	Hepatitis C Virus Infection Induces Autocrine Interferon Signaling by Human Liver Endothelial Cells and Release of Exosomes, Which Inhibits Viral Replication. <i>Gastroenterology</i> , 2015, 148, 392-402.e13.	0.6	107
3	A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. <i>Journal of Hepatology</i> , 2014, 60, 1203-1211.	1.8	99
4	Functional Maturation of Induced Pluripotent Stem Cell Hepatocytes in Extracellular Matrix—A Comparative Analysis of Bioartificial Liver Microenvironments. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1257-1267.	1.6	95
5	Resetting the transcription factor network reverses terminal chronic hepatic failure. <i>Journal of Clinical Investigation</i> , 2015, 125, 1533-1544.	3.9	89
6	Assembly and Function of a Bioengineered Human Liver for Transplantation Generated Solely from Induced Pluripotent Stem Cells. <i>Cell Reports</i> , 2020, 31, 107711.	2.9	81
7	Negative reciprocal regulation between Sirt1 and Per2 modulates the circadian clock and aging. <i>Scientific Reports</i> , 2016, 6, 28633.	1.6	80
8	Biotechnology Challenges to In Vitro Maturation of Hepatic Stem Cells. <i>Gastroenterology</i> , 2018, 154, 1258-1272.	0.6	78
9	Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. <i>Cell Metabolism</i> , 2019, 30, 385-401.e9.	7.2	75
10	Future Economics of Liver Transplantation: A 20-Year Cost Modeling Forecast and the Prospect of Bioengineering Autologous Liver Grafts. <i>PLoS ONE</i> , 2015, 10, e0131764.	1.1	71
11	Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems. <i>Experimental Biology and Medicine</i> , 2017, 242, 1605-1616.	1.1	66
12	The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis. <i>Hepatology</i> , 2012, 55, 1529-1539.	3.6	59
13	Induced Pluripotent Stem Cell-Derived Endothelial Cells. <i>American Journal of Pathology</i> , 2019, 189, 502-512.	1.9	51
14	Guide to the Assessment of Mature Liver Gene Expression in Stem Cell-Derived Hepatocytes. <i>Stem Cells and Development</i> , 2019, 28, 907-919.	1.1	46
15	A Multiscale Agent-Based in silico Model of Liver Fibrosis Progression. <i>Frontiers in Bioengineering and Biotechnology</i> , 2014, 2, 18.	2.0	45
16	SIRT1 Disruption in Human Fetal Hepatocytes Leads to Increased Accumulation of Glucose and Lipids. <i>PLoS ONE</i> , 2016, 11, e0149344.	1.1	40
17	Molecular overview of progressive familial intrahepatic cholestasis. <i>World Journal of Gastroenterology</i> , 2020, 26, 7470-7484.	1.4	37
18	Clinical Hepatocyte Transplantation: What Is Next?. <i>Current Transplantation Reports</i> , 2017, 4, 280-289.	0.9	28

#	ARTICLE	IF	CITATIONS
19	Liver-enriched transcription factor expression relates to chronic hepatic failure in humans. <i>Hepatology Communications</i> , 2018, 2, 582-594.	2.0	28
20	Assembly of Human Organs from Stem Cells to Study Liver Disease. <i>American Journal of Pathology</i> , 2014, 184, 348-357.	1.9	21
21	Regulation of Cytosolic Sulfotransferases in Models of Human Hepatocyte Development. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1146-1156.	1.7	16
22	Modeling and therapy of human liver diseases using induced pluripotent stem cells: How far have we come?. <i>Hepatology</i> , 2011, 53, 708-711.	3.6	13
23	The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone. <i>Seminars in Liver Disease</i> , 2021, 41, 213-224.	1.8	13
24	Transplantation of bioengineered liver capable of extended function in a preclinical liver failure model. <i>American Journal of Transplantation</i> , 2022, 22, 731-744.	2.6	13
25	Cellular Location of HNF4 α is Linked With Terminal Liver Failure in Humans. <i>Hepatology Communications</i> , 2020, 4, 859-875.	2.0	12
26	A Pre-Clinical Large Animal Model of Sustained Liver Injury and Regeneration Stimulus. <i>Scientific Reports</i> , 2018, 8, 14987.	1.6	10
27	Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target. <i>Journal of Personalized Medicine</i> , 2021, 11, 619.	1.1	8
28	Hepatocyte Nuclear Factor 4 alpha 2 Messenger RNA Reprograms Liver-enriched Transcription Factors and Functional Proteins in End-stage Cirrhotic Human Hepatocytes. <i>Hepatology Communications</i> , 2021, 5, 1911-1926.	2.0	7
29	Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors. <i>Experimental Biology and Medicine</i> , 2021, 246, 2420-2441.	1.1	5
30	Transmembrane channel activity in human hepatocytes and cholangiocytes derived from induced pluripotent stem cells. <i>Hepatology Communications</i> , 2022, 6, 1561-1573.	2.0	4
31	Biofabrication of Autologous Human Hepatocytes for Transplantation: How Do We Get There?. <i>Gene Expression</i> , 2019, 19, 89-95.	0.5	3
32	Synthetic human livers for modeling metabolic diseases. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 224-230.	1.0	2
33	Reply to: "Is the pathway of energy metabolism modified in advanced cirrhosis?". <i>Journal of Hepatology</i> , 2014, 61, 453.	1.8	0